SUCLG2 plays an important role not only in neurometabolic disorders and Alzheimer’s disease (Ramirez et al., 2014; Chinopoulos et al., 2019), but also in tumors (Lin et al., 2020). This evidence concerns the gene SUCLG2 and early-onset autosomal dominant Alzheimer disease.